Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy

Journal of Virology

Volumn 75, Issue 11, 2001, Pages 4999-5008

  Bacheler, Lee ^a   Jeffrey, Susan ^a   Hanna, George ^b   D'Aquila, Richard ^b   Wallace, Lany ^a   Logue, Kelly ^a   Cordova, Beverly ^a   Hertogs, Kurt ^c   Larder, Brendan ^d   Buckery, Renay ^a   Baker, David ^e   Gallagher, Karen ^a   Scarnati, Helen ^a   Tritch, Radonna ^a   Rizzo, Chris ^a  

^a DUPONT COMPANY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Virco BVBA   (Belgium)

^d Virco UK Ltd   (United Kingdom)

^e E336/36B Experimental Station ^*

Author keywords

[No Author keywords available]

Indexed keywords

DELAVIRDINE; EFAVIRENZ; INDINAVIR; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; CROSS RESISTANCE; ENZYME INHIBITION; GENETIC CODE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MONONUCLEAR CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SITE DIRECTED MUTAGENESIS; STRAIN DIFFERENCE; VIRUS ISOLATION; VIRUS LOAD; VIRUS MUTANT; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS RESISTANCE;

AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; CELLS, CULTURED; CLINICAL TRIALS, PHASE II; COHORT STUDIES; DELAVIRDINE; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; GENOTYPE; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LEUKOCYTES, MONONUCLEAR; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; MUTATION; NEVIRAPINE; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT FAILURE;

EID: 0035037383     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.11.4999-5008.2001     Document Type: Article

References (32)

1. Bacheler, L., L. Ploughman, K. Hertogs, and B. Larder. 2000. Impact of baseline NNRTI resistance on the efficacy of efavirenz combination therapy in NNRTI therapy-naive patients (Study DMP 266-006). Antivir. Ther. 5(Suppl.):70.
2. Bacheler, L. T., Elizabeth D. Anton, P. Kudish, D. Baker, J. Bunville, K. Krakowski, L. Boiling, M. Aujay, X. Wang, D. Ellis, M. F. Becker, A. L. Lasut, H. J. George, D. R. Spalding, G. Hollis, and K. Abremski. 2000. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob. Agents Chemother. 44:475-484.
3. Cheeseman, S., D. Havlir, M. McLaughlin, T. Greenough, J. Sullivan, D. Hall, S. Hattox, S. Spector, D. Stein, M. Myers, et al. 1995. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquir. Immune Defic. Syndr. Hum. Retrovirol. 8:141-151.
4. Demeter, L. M., R. W. Shafer, P. M. Meehan, J. Holden-Wiltse, M. A. Fischl, W. W. Freimuth, M. F. Para, and R. C. Reichman. 2000. Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260). Antimicrob. Agents Chemother. 44:794-797.
5. Falloon, J., S. Piscitelli, S. Vogel, B. Sadler, H. Mitsuya, M. Kavlick, K. Yoshimura, M. Rogers, S. LaFon, D. Manion, H. Lane, and H. Masur. 2000. Combination therapy with amprenavir, ahacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity. Clin. Infect. Dis. 30:313-318.
6. Harrigan, P., W. Verbiest, B. Larder, K. Hertogs, J. Tilley, J. Raboud, and J. Montaner. 2000. Impact of moderate decreases in baseline NNRTI susceptibility on response to antiretroviral therapy. Antivir. Ther. 5(Suppl. 3): 68.
7. Haubrich, R., J. Whitcomb, P. Keiser, C. Kemper, M. Witt, M. Dube, D. Forthal, M. Leibowitz, J. Hwang, A. Rigby, N. Hellman, J. Mccutchan, D. Richman, and the CCTG. 2000. Non-nucleoside reverse transcriptase inhibitor viral hypersensitivity is common and improved short-term virological response. Antivir. Ther. 5(Suppl. 3):69.
8. Hertogs, K., M.-P. de Bèthune, V. Miller, T. Ivens, P. Schel, A. Van Cauwenberge, C. Van Den Eynde, V. Van Gerwen, H. Azijn, M. Van Houtte, F. Peeters, S. Staszewski, M. Conant, S. Bloor, S. Kemp, B. Larder, and R. Pauwels. 1998. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob. Agents Chemother. 42:269-276.
9. Jadhav, P., P. Ala, F. Woerner, C. Chang, S. Garber, E. Anton, and L. Bacheler. 1997. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV. J. Med. Chem. 40:181-191.
10. Japour, A. J., D. I. Mayers, V. A. Johnson, D. R. Kuritzkes, L. A. Beckett, J.-M. Arduino, J. Lane, R. J. Black, P. Reichelderfer, R. T. D'Aquila, C. S. Crumpacker, The RV-43 Study Group, and The AIDS Clinical Trials Group Virology Committee Resistance Working Group. 1993. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 37:1095-1101.
11. Johnson, V. A. 1990. Evaluation of candidate anti-HIV agents in vitro, p. 225-237. In A. Aldovini and B. D. Walker (ed.), Techniques in HIV research. Stockson Press, New York, N.Y.
12. Johnson, V. A., and R. E. Byington. 1990. Quantitative assays for virus infectivity, p. 71-77. In A. Aldovini and B. D. Walker (ed.). Techniques in HIV research. Stockson Press, New York, N.Y.
13. Kemp, S., S. Bloor, A. Van Cauwenberge, D. Koning, C. Van den Eynde, B. Larder, and K. Hertogs. 1999. Analysis of 5,000 HIV-1 clinical samples reveals complex non-nucleoside RT inhibitor resistance patterns. Antivir. Ther. 4:20.
14. Kleim, J., M. Winters, A. Dunkler, J. Suarez, G. Riess, I. Winkler, J. Balzarini, D. Oette, and T. Merigan. 1999. Antiviral activity of the human immunodeficiency virus type 1-specific nonnucleoside reverse transcriptase inhibitor HBY 097 alone and in combination with zidovudine in a phase II study. HBY 097/2001 Study Group. J. Infect. Dis. 179:709-713.
15. Little, S., E. Daar, A. R. D., P. Keiser, E. Connick, J. Whitcomb, N. Hellmann, C. Petropoulos, L. Sutton, J. Pitt, E. Rosenberg, R. Koup, B. Walker, and D. Richman. 1999. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 282:1142-1149.
16. Martinez-Picado, J., M. P. DePasquale, N. Kartsonis, G. J. Hanna, J. Wong, D. Finzi, E. Rosenberg, H. F. Gunthard, L. Sutton, A. Savara, C. Petropolous, N. Hellman, B. D. Walker, D. D. Richman, R. Siliciano, and R. T. D'Aquila. 2000. Antiretroviral resistance during successful therapy of human immunodeficiency virus type 1 infection. Proc. Natl. Acad. Sci. USA 97: 10948-10953.
17. Mellors, J. W., G. E. Dutschman, G. J. Im, E. Tramontan, S. R. Winkler, and Y. C. Cheng. 1992. In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to nonnucleoside inhibitors of reverse transcriptase. Mol. Pharmacol. 41:446-451. (Erratum, 42:174.)
18. Miller, V., M.-P.. de Bèthune, A. Kober, M. Stürmer, K. Hertogs, R. Pauwels, P. Stoffels, and S. Staszewski. 1998. Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride. Antimicrob. Agents Chemother. 42:3123-3129.
19. Montaner, J., P. Reiss, D. Cooper, S. Vella, M. Harris, B. Conway, M. Wainberg, D. Smith, P. Robinson, D. Hall, M. Myers, and J. Lange. 1998. A randomized, double-blind trial comparing combinations of nevirapine. didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 279:930-937.
20. Pelemans, H., R. Esnouf, A. Dunkler, M. A. Parniak, A.-M. Vandamme, A. Karlsson, E. De Clercq, J.-P. Kleim, and J. Balzarini. 1997. Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1. J. Virol. 71:8195-8203.
21. Richman, D. D., D. Havlir, J. Corbeil, D. Looney, C. Ignacio, S. A. Spector, J. Sullivan, S. Cheeseman, K. Barringer, D. Pauletti, C.-K. Shih, M. Myers, and J. Griffin. 1994. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68:1660-1666.
22. Richman, D., C. Shih, I. Lowy, J. Rose, P. Prodanovich, S. Goff, and J. Grifin. 1991. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc. Natl. Acad. Sci. USA 88:11241-11245.
23. Schinazi, R., B. Larder, and J. Mellors. 2000. Mutations in retroviral genes associated with drug resistance: 2000-2001 update. Int. Antivir. News 8:65-91.
24. Shulman, N., A. Zolopa, D. Passaro, U. Murlidharan, D. Israleski, C. Brosgart, M. Miller, S. V. Doren, R. Shafer, and D. Katzenstein. 2000. Efavirenz-and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologie response. J. Acquir. Immune Defic. Syndr. 23:221-226.
25. Smerdon, S., J. Jager, J. Wang, L. Kohlstaedt, A. Chirino, J. Friedman, P. Rice, and T. Steitz. 1994. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type I. Proc. Natl. Acad. Sci. USA 91:3911-3915.
26. Staszewski, S., J. Morales-Ramirez, K. T. Tashima, A. Rachlis, D. Skiest, J. Stanford, R. Stryker, P. Johnson, D. F. Labriola, D. Farina, D. J. Manion, and N. M. Ruiz. 1999. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N. Engl. J. Med. 341:1865-1873.
27. Vandamme, A., Z. Debyser, R. Pauwels, K. De Vreese, P. Goubau, M. Youle, B. Gazzard, P. A. Stoffels, G. F. Cauwenbergh, J. Anne, et al. 1994. Characterization of HIV-1 strains isolated from patients treated with TIBO R82913. AIDS Res. Hum. Retrovir. 10:39-46.
28. Villahermose, M., I. Beck, L. Perez-Alvarez, C. Contreras, L. Frenkel, S. Osmanov, and R. Najera. 2000. Development of a new highly specific assay for detection and quantification of mulitple drug resistance mutations in HIV-1 reverse transcriptase. Antivir. Ther. 5(Suppl. 3):57.
29. Wegner, S. A., S. K. Brodine, J. R. Mascola, S. A. Tasker, R. A. Shaffer, M. J. Starkey, A. Barile, G. J. Martin, N. Aronson, W. W. Emmons, K. Stephan, S. Bloor, J. Vingerhoets, K. Hertogs, and B. Larder. 2000. Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naive HIV-1 infected US military personnel. AIDS 14:1009-1015.
30. Winslow, D., E. Anton, R. Horlick, R. Zagursky, R. Tritch, H. Scarnati, K. Ackerman, and L. Bacheler. 1994. Construction of infectious molecular clones of HIV-1 containing defined mutations in the protease gene. Biochem. Biophys. Res. Commun. 205:1651-1657.
31. Winslow, D., S. Garber, C. Reid, H. Scarnati, D. Baker, M. Rayner, and E. Anton. 1996. Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266. AIDS 10:1205-1209.
32. Young, S. D., S. F. Britcher, L. O. Tran, L. S. Payne, W. C. Lumma, T. A. Lyle, J. R. Huff, P. S. Anderson, D. B. Olsen, S. S. Carroll, D. J. Pettibone, J. A. O'Brien, R. G. Ball, S. K. Balani, J. H. Lin, I-W. Chen, W. A. Schleif, V. V. Sardana, W. J. Long, V. W. Byrnes, and E. A. Emini. 1995. L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 39:2602-2605.